Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $113.8 million.

  • Cytek Biosciences' Total Non-Current Liabilities rose 982.9% to $113.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.8 million, marking a year-over-year increase of 982.9%. This contributed to the annual value of $101.4 million for FY2024, which is 246.26% up from last year.
  • As of Q3 2025, Cytek Biosciences' Total Non-Current Liabilities stood at $113.8 million, which was up 982.9% from $113.3 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Total Non-Current Liabilities high stood at $113.8 million for Q3 2025, and its period low was $46.2 million during Q2 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $98.2 million (2023), whereas its average is $89.2 million.
  • Per our database at Business Quant, Cytek Biosciences' Total Non-Current Liabilities surged by 7386.27% in 2022 and then crashed by 609.58% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Total Non-Current Liabilities stood at $56.7 million in 2021, then skyrocketed by 62.82% to $92.3 million in 2022, then rose by 7.17% to $99.0 million in 2023, then increased by 2.46% to $101.4 million in 2024, then grew by 12.26% to $113.8 million in 2025.
  • Its last three reported values are $113.8 million in Q3 2025, $113.3 million for Q2 2025, and $100.6 million during Q1 2025.